Literature DB >> 20538467

Identification of novel inhibitors for a low molecular weight protein tyrosine phosphatase via virtual screening.

Kristoff T Homan1, Deepa Balasubramaniam, Adam P R Zabell, Olaf Wiest, Paul Helquist, Cynthia V Stauffacher.   

Abstract

The human cytoplasmic protein tyrosine phosphatase (HCPTP) has been identified as a potential target for inhibition in order to downregulate metastatic transformation in several human epithelial cancers such as breast, prostate and colon cancer. Docking with two scoring functions on both isoforms of HCPTP was employed as an initial virtual screen to identify potential inhibitors. Compounds identified as potential inhibitors via this in silico screen were subjected to kinetic analysis in order to validate their selection as improved inhibitors. Eleven compounds with IC50's of less than 100 microM were identified in a single concentration screen. Five of these compounds were determined to have an IC50 of less than 10 microM; however, all but one of these compounds inhibited via non-specific aggregation. The validated effective inhibitor, which is based on a naphthyl sulfonic acid, strongly resembles a previously synthesized rationally designed azaindole phosphonic acid. This similarity suggests subsequent inhibitor optimization based on this scaffold may generate effective inhibitors of HCPTP. The structural elements of the computationally identified inhibitors are discussed to analyze the combined use of rational design and virtual screening to reduce false negatives in the identification of multiple strong inhibitors of HCPTP. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538467      PMCID: PMC6031871          DOI: 10.1016/j.bmc.2010.04.050

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  27 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.

Authors:  Susan L McGovern; Emilia Caselli; Nikolaus Grigorieff; Brian K Shoichet
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

3.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Fontanini; S Cuccato; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

4.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.

Authors:  Thomas A Halgren; Robert B Murphy; Richard A Friesner; Hege S Beard; Leah L Frye; W Thomas Pollard; Jay L Banks
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

5.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

6.  A detergent-based assay for the detection of promiscuous inhibitors.

Authors:  Brian Y Feng; Brian K Shoichet
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

7.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Authors:  Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

8.  Fragment-based substrate activity screening method for the identification of potent inhibitors of the Mycobacterium tuberculosis phosphatase PtpB.

Authors:  Matthew B Soellner; Katherine A Rawls; Christoph Grundner; Tom Alber; Jonathan A Ellman
Journal:  J Am Chem Soc       Date:  2007-07-18       Impact factor: 15.419

Review 9.  Automated docking of flexible ligands: applications of AutoDock.

Authors:  D S Goodsell; G M Morris; A J Olson
Journal:  J Mol Recognit       Date:  1996 Jan-Feb       Impact factor: 2.137

10.  Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion.

Authors:  Christa L Cortesio; Keefe T Chan; Benjamin J Perrin; Nicholas O Burton; Sheng Zhang; Zhong-Yin Zhang; Anna Huttenlocher
Journal:  J Cell Biol       Date:  2008-03-10       Impact factor: 10.539

View more
  3 in total

1.  Specificity of HCPTP variants toward EphA2 tyrosines by quantitative selected reaction monitoring.

Authors:  Deepa Balasubramaniam; Lake N Paul; Kristoff T Homan; Mark C Hall; Cynthia V Stauffacher
Journal:  Protein Sci       Date:  2011-05-23       Impact factor: 6.725

Review 2.  Voltage sensitive phosphatases: emerging kinship to protein tyrosine phosphatases from structure-function research.

Authors:  Kirstin Hobiger; Thomas Friedrich
Journal:  Front Pharmacol       Date:  2015-01-10       Impact factor: 5.810

3.  Ligand pose and orientational sampling in molecular docking.

Authors:  Ryan G Coleman; Michael Carchia; Teague Sterling; John J Irwin; Brian K Shoichet
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.